Epidemiologic Research on Emerging Risk Factors and Liver Cancer Susceptibility (R01 Clinical Trial Not Allowed)
ID: 337478Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/337478

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-22-083.html
Timeline
    Description

    The National Institutes of Health (NIH) is offering a funding opportunity titled "Epidemiologic Research on Emerging Risk Factors and Liver Cancer Susceptibility (R01 Clinical Trial Not Allowed)" aimed at promoting research into novel risk factors associated with liver cancer in the United States. This initiative seeks to investigate innovative hypotheses regarding biological, environmental, and social factors, as well as their interactions with established risks like viral hepatitis, to better understand their roles in the development of liver cancer, particularly hepatocellular carcinoma and its subtypes. The funding is intended to support diverse research efforts that leverage existing data and biospecimens, with a focus on non-viral factors such as obesity and environmental pollutants, and is open to a wide range of eligible applicants, including various educational and community organizations. Interested parties should note that the application deadline is May 7, 2025, and they can find more information and submission guidelines at the provided NIH link or contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov for further inquiries.

    Point(s) of Contact
    OERWebmaster03@od.nih.gov
    Files
    Title
    Posted
    PAR-22-083-Full-Announcement.html
    PAR-22-083.html
    The Department of Health and Human Services, through the National Institutes of Health (NIH), is announcing a funding opportunity aimed at promoting epidemiologic research on emerging risk factors associated with liver cancer in the United States. The objective is to investigate novel hypotheses regarding biological, environmental, and social risk factors and their interaction with established risks, such as viral hepatitis, in the development of liver cancer (hepatocellular carcinoma and subtypes). This funding announcement, under the R01 Research Project Grant mechanism, encourages the submission of innovative applications that leverage existing data and biospecimens. Awards will prioritize research into non-viral factors like obesity, diabetes, and environmental pollutants, as well as their roles in liver cancer risk across diverse U.S. populations. The application process is open to a wide range of eligible institutions, including higher education and nonprofit organizations, and requires compliance with specific submission guidelines. This initiative calls for a strong focus on identifying population-based risk factors to inform liver cancer prevention strategies, with an anticipated project duration of up to five years and no limit on application budgets.
    Similar Opportunities
    Epidemiologic Research on Emerging Risk Factors and Liver Cancer Susceptibility (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for epidemiologic research focused on emerging risk factors associated with liver cancer in the United States, specifically through the R01 grant mechanism. This initiative aims to investigate novel hypotheses regarding biological, environmental, and social factors, as well as their interactions with established risk factors like viral hepatitis, to better understand their role in the development of hepatocellular carcinoma and other liver cancer types. The program encourages applications that explore non-viral contributors, such as obesity and diabetes, and seeks to produce insights that will inform evidence-based strategies for liver cancer prevention and control. Interested applicants, including higher education institutions, nonprofit organizations, and foreign entities, must submit their proposals by February 5, 2025, and can find additional information at NIH Grants. For inquiries, contact NIH Grants Information at grantsinfo@nih.gov.
    Epidemiologic Research on Emerging Risk Factors and Liver Cancer Susceptibility (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity for epidemiologic research on emerging risk factors associated with liver cancer in the United States, specifically through the R21 Clinical Trial Not Allowed mechanism. This initiative aims to explore innovative hypotheses regarding biological, environmental, and social risk factors, while excluding applications focused solely on viral hepatitis as the etiologic factor. The research is crucial for informing prevention strategies and addressing the rising rates of liver cancer, particularly hepatocellular carcinoma, among various U.S. populations. Interested applicants can apply for a budget of up to $275,000 over two years, with the application process opening on January 16, 2025, and the submission deadline set for May 7, 2025. For further inquiries, applicants may contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PA-25-123.html.
    Epidemiologic Research on Emerging Risk Factors and Liver Cancer Susceptibility (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the R21 Exploratory/Developmental Research Grant focused on epidemiologic research related to liver cancer susceptibility and emerging risk factors. This funding opportunity aims to investigate both established risk factors, such as viral hepatitis, and novel influences, including environmental and social factors, that contribute to liver cancer incidence in the United States. The initiative underscores the increasing recognition of liver cancer's rising incidence and the need for targeted public health strategies, with a funding limit of $275,000 available over two years. Interested applicants must adhere to NIH guidelines and submit their applications by May 7, 2025; for further inquiries, they can contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov.
    Interventions to Address Disparities in Liver Diseases and Liver Cancer (R01 - Clinical Trials Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Interventions to Address Disparities in Liver Diseases and Liver Cancer," aimed at supporting research interventions that target health disparities in liver diseases and liver cancer among marginalized populations in the United States. This initiative encourages researchers to propose multi-level and multi-domain approaches that address social determinants of health, with a focus on improving screening, treatment, and health outcomes for affected groups, including racial and ethnic minorities and individuals with lower socioeconomic status. The grant has no specific budget limit and allows for a maximum project period of five years, with applications accepted starting September 5, 2024. Interested applicants can find more information and contact NIH Grants Information at grantsinfo@nih.gov for inquiries.
    Co-infection and Cancer (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) has announced a funding opportunity titled "Co-infection and Cancer (R01 Clinical Trial Not Allowed)" aimed at enhancing the understanding of infection-related cancers, particularly the roles of co-infection in cancer development. This initiative encourages mechanistic and epidemiologic studies that explore how infections by multiple agents—both pathogenic and non-pathogenic—can influence cancer risk and progression, with a focus on known oncogenic agents, excluding HIV. Given the significant proportion of cancer cases linked to infectious agents, this research is crucial for developing novel prevention and treatment strategies. Interested applicants, including a variety of educational institutions and organizations, particularly those from underrepresented groups, must submit their applications by November 5, 2025, and can find further details and guidelines at the NIH website or contact NIH Grants Information at grantsinfo@nih.gov.
    Co-infection and Cancer (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Co-infection and Cancer (R01 Clinical Trial Not Allowed)" aimed at enhancing the understanding of infection-related cancers, particularly focusing on the roles of co-infections with various pathogens, excluding HIV. This initiative seeks to investigate the mechanisms and epidemiology of cancer linked to co-infections, addressing significant gaps in knowledge and emphasizing health disparities in affected populations. The funding allows for a five-year project period with no budget limit, requiring strong preliminary data, and applications are encouraged from a diverse range of eligible entities, including higher education institutions and community-based organizations. Interested applicants should note that the earliest submission date is January 5, 2025, with a final deadline of January 8, 2026; for further inquiries, they can contact NIH Grants Information at grantsinfo@nih.gov.
    Population Approaches to Reducing Alcohol-related Cancer Risk (R01 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the "Population Approaches to Reducing Alcohol-related Cancer Risk" funding opportunity, designated as R01 Clinical Trial Optional. This initiative aims to support interdisciplinary research focused on increasing awareness of the link between alcohol consumption and cancer risk, altering social norms regarding alcohol use, evaluating alcohol policy approaches, and developing population-level interventions to mitigate alcohol-related cancer risks. The funding is particularly relevant for addressing alcohol use disorders and disparities faced by underrepresented minority populations, with applications due between January 5, 2024, and October 5, 2026, and project periods extending up to five years. There is no specific budget limit for applications, which should reflect the actual needs of the proposed projects. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov, and additional details can be found at the provided link: https://grants.nih.gov/grants/guide/pa-files/PAR-23-244.html.
    Cancer Epidemiology Cohorts: Building the Next Generation of Research Cohorts (U01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), is offering a funding opportunity titled "Cancer Epidemiology Cohorts: Building the Next Generation of Research Cohorts (U01 Clinical Trial Not Allowed)." This initiative aims to establish population-based cancer epidemiology cohorts to address critical knowledge gaps in cancer etiology and survivorship, particularly focusing on engaging diverse and underserved populations. The project will support methodological work necessary for cohort development, emphasizing community engagement and the validation of cancer outcomes linked to population-based registries. Interested applicants, including educational institutions, nonprofits, and local governments, must submit their proposals by February 28, 2025, and can find additional details at the provided NIH link or contact the NIH OER Webmaster at OERWebmaster03@od.nih.gov for inquiries.
    Co-infection and Cancer (R21 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Co-infection and Cancer (R21 Clinical Trial Not Allowed)" aimed at enhancing research on the mechanisms and epidemiology of co-infections in relation to cancer development. This grant seeks innovative proposals that investigate how co-infections, particularly those involving known oncogenic agents (excluding HIV), may influence carcinogenesis and contribute to cancer disparities among diverse populations. The maximum funding amount available for each application is $275,000 over a two-year period, with applications due by November 16, 2025. Eligible applicants include a wide range of institutions and organizations, and inquiries can be directed to NIH Grants Information at grantsinfo@nih.gov.
    Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R01 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Cancer Institute (NCI), has announced a Notice of Funding Opportunity (NOFO) titled "Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes" (PAR-23-254). This initiative aims to encourage researchers to conduct innovative analyses of existing datasets, including clinical, genomic, and epidemiological data, to address critical questions related to cancer risk, treatment responses, and health outcomes. By leveraging previously collected data, the program seeks to enhance understanding of cancer-related issues while allowing for a limited generation of new data for validation purposes. Eligible applicants include a wide range of institutions, with funding capped at $350,000 annually for up to five years. Applications will be accepted from October 2023 until June 2026, and interested parties can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.